(Finance) – Excellent performance for Inogentrading up 6.35%, after the FDA approved the SIMEOX 200 Airway Clearance Device for bronchial drainage in patients with chronic respiratory diseases.
On a weekly basis, the stock’s trend is more solid than that of Nasdaq 100. At the moment, therefore, the appeal of investors is aimed more decisively at Inogen compared to the reference index.
The medium-term scenario of Inogen confirms the negative trend of the curve. However, the analysis of the short-term chart highlights an easing of the bearish phase preparatory to a rise towards the first resistance area seen at USD 9.31. Support at 8.863. Any positive elements support the achievement of a new top seen in the 9.76 area.